Skip to main content
OpenTrials
Completed

NCT Number: NCT03907722

The 3q25 rs2305619 Polymorphism Associates With Microvascular Obstruction in STEMI

The investigators enrolled 217 patients with acute STEMI undergoing primary PCI. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

STEMI Cardiovascular Diseases Heart Diseases Infarction Ischemia Microvascular Coronary Artery Disease Myocardial Infarction Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms ST Elevation Myocardial Infarction Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Indonesian Cardiovascular Research Center

Jakarta, DKI Jakarta, 11420, Indonesia

About this study

The investigators enrolled 217 patients with acute STEMI undergoing primary PCI in a tertiary care academic cardiovascular center. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit. The primary outcome of the study was the incidence of coronary microvascular obstruction defined as thrombolysis in myocardial infarction (TIMI) grade <3 flow after primary PCI or TIMI grade 3 flow with myocardial blush grade 0 or 1. Patients were grouped based on the genotypic variants (AA, AG and GG). The primary outcome was compared among the three variants, as well as the PTX3 concentration and 30-day mortality.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with acute STEMI with symptom onset <12 h and treated by primary PCI

Exclusion criteria

  • STEMI patients who received fibrinolytic therapy

Treatment and study plan

Long pentraxin 3

Other

Primary PCI

Primary outcomes

  1. Incidence of microvascular obstruction

    Time frame: Immediate after pci

    Percentage

Secondary outcomes

  1. Incidence of mortality

    Time frame: 30 days

    Percentage

Sponsors and collaborators

Lead sponsor

Indonesian Cardiovascular Research Center

Other

Registry information

Official study title

The 3q25 rs2305619 Polymorphism is Associated With Coronary Microvascular Obstruction Following Primary Angioplasty for Acute ST-segment Elevation Myocardial Infarction

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Apr 9, 2019
Registry last updated
Apr 11, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.